Inspection prep notes · Sterility and contamination control
Media fill
Also called: process simulation, aseptic process simulation
FDA looks less at whether a media fill was run than at whether it simulated the hardest conditions of actual production. The findings below are quoted from warning letters.
What inspectors cited
1Worst-case conditions and actual batch size were not simulated
process simulation (i.e., media-fill) studies should be conducted under “worst-case” scenarios (e.g., simulating largest batch size, longest processing time, and routine & non-routine interventions) …
FDA Warning Letter · Turbare Manufacturing · 2025-12-02 · View document
Data indicated that the total number of units in your media fills were substantially smaller than your aseptically produced commercial batch sizes and did not sufficiently represent the contamination risks associated with your aseptic processing lines.
FDA Warning Letter · Bausch & Lomb Inc. · 2026-09-15
2Fewer interventions, and fewer kinds, than in actual production
The intervention of (b)(4) was simulated approximately (b)(4) times during a media fill, but production records indicate a significantly higher occurrence of this intervention.
FDA Warning Letter · Baxter International Inc. · 2026-10-20 · View document
We observed significantly more interventions performed during routine batch manufacturing that were either not simulated or reduced in quantity in media fills, as compared to what was observed during production.
FDA Warning Letter · Daewoo Pharmaceutical Co., Ltd. · 2025-07-15 · View document
3Contaminated units were found but the cause was not investigated
Your firm failed to investigate the positive growth and discarded all units that showed signs of microbial contamination.
FDA Warning Letter · Annovex Pharma, Inc. · 2025-03-25 · View document
Neither batch was evaluated for an assignable cause of contamination or followed by successful revalidation.
FDA Warning Letter · Regenerative Processing Plant, LLC · 2024-09-06 · View document
4Filled units were removed, or only some were incubated
You removed integral units (i.e., units with intact container-closure systems) from media fills without adequate justification and failed to incubate all integral units for the full (b)(4) period.
FDA Warning Letter · Global Pharma Healthcare Private Limited · 2023-11-14 · View document
your firm incubated and examined a select number of filled units based on an acceptable quality level (AQL) sampling plan, rather than all integral, filled units.
FDA Warning Letter · Regenerative Processing Plant, LLC · 2024-09-06 · View document
5Operators were not qualified through media fills
one of your operators had not been requalified to perform PET drug manufacturing using process simulations (media fills) since April 2021.
FDA Warning Letter · 3D Imaging Drug Design and Development LLC · 2025-12-16 · View document
Your firm also did not require operators to participate in a media fill prior to working in the aseptic processing operation.
FDA Warning Letter · Daewoo Pharmaceutical Co., Ltd. · 2025-07-15 · View document
Questions to check against your procedures
- Is the media fill protocol based on the largest batch size and the longest filling time?
- Is the number of units filled comparable to a commercial batch? If not, is the justification documented?
- Are the types and counts of interventions in production records tallied and carried into the media fill? Are unplanned interventions recorded too?
- When a media fill yields contaminated units, does the procedure lead to a root cause investigation and revalidation?
- Are all integral units incubated? If any are excluded, is the reason recorded?
- Do all aseptic operators take part in a media fill before working and at the set interval? Is there a control that catches anyone who was missed?
Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.